Niaspan, for treatment of primary hyperlipidemia and mixed dyslipidemia, has $1.1 billion in annual sales in the US.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched generic Niaspan in the US. Niaspan had $1.12 billion in annual sales in the US, according to IMS data as of June 30, 2013. Teva will sell generic Niaspan in 500, 750, and 1000 milligram tablets. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Brand Niaspan is sold by AbbVie Inc. (Nasdaq: ABBV) and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
Published by Globes [online], Israel business news - www.globes-online.com - on September 22, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
Shiri Habib-Valdhorn and Globes' correspondent